179 related articles for article (PubMed ID: 24288670)
1. Circulating microRNAs and kallikreins before and after radical prostatectomy: are they really prostate cancer markers?
Egidi MG; Cochetti G; Serva MR; Guelfi G; Zampini D; Mechelli L; Mearini E
Biomed Res Int; 2013; 2013():241780. PubMed ID: 24288670
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine.
Fredsøe J; Rasmussen AKI; Thomsen AR; Mouritzen P; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Eur Urol Focus; 2018 Dec; 4(6):825-833. PubMed ID: 28753866
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.
Kulda V; Topolcan O; Kucera R; Kripnerova M; Srbecka K; Hora M; Hes O; Klecka J; Babuska V; Rousarova M; Benson V; Pesta M
Anticancer Res; 2016 Sep; 36(9):4787-93. PubMed ID: 27630329
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic performance of expression of PCA3, Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer.
Roberts MJ; Chow CW; Schirra HJ; Richards R; Buck M; Selth LA; Doi SA; Samaratunga H; Perry-Keene J; Payton D; Yaxley J; Lavin MF; Gardiner RA
Prostate; 2015 Apr; 75(5):539-49. PubMed ID: 25597828
[TBL] [Abstract][Full Text] [Related]
5. Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer.
Watahiki A; Macfarlane RJ; Gleave ME; Crea F; Wang Y; Helgason CD; Chi KN
Int J Mol Sci; 2013 Apr; 14(4):7757-70. PubMed ID: 23574937
[TBL] [Abstract][Full Text] [Related]
6. Circulating microRNAs in plasma before and after radical prostatectomy.
McDonald AC; Raman JD; Shen J; Liao J; Pandya B; Vira MA
Urol Oncol; 2019 Nov; 37(11):814.e1-814.e7. PubMed ID: 31421994
[TBL] [Abstract][Full Text] [Related]
7. Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer.
Kachakova D; Mitkova A; Popov E; Popov I; Vlahova A; Dikov T; Christova S; Mitev V; Slavov C; Kaneva R
DNA Cell Biol; 2015 Mar; 34(3):189-200. PubMed ID: 25521481
[TBL] [Abstract][Full Text] [Related]
8. Cell-free DNA concentration and fragment size as a biomarker for prostate cancer.
Chen E; Cario CL; Leong L; Lopez K; Márquez CP; Chu C; Li PS; Oropeza E; Tenggara I; Cowan J; Simko JP; Chan JM; Friedlander T; Wyatt AW; Aggarwal R; Paris PL; Carroll PR; Feng F; Witte JS
Sci Rep; 2021 Mar; 11(1):5040. PubMed ID: 33658587
[TBL] [Abstract][Full Text] [Related]
9. miR-183 in prostate cancer cells positively regulates synthesis and serum levels of prostate-specific antigen.
Larne O; Östling P; Haflidadóttir BS; Hagman Z; Aakula A; Kohonen P; Kallioniemi O; Edsjö A; Bjartell A; Lilja H; Lundwall Å; Ceder Y
Eur Urol; 2015 Oct; 68(4):581-8. PubMed ID: 25556023
[TBL] [Abstract][Full Text] [Related]
10. Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer.
Souza MF; Kuasne H; Barros-Filho MC; Cilião HL; Marchi FA; Fuganti PE; Paschoal AR; Rogatto SR; Cólus IMS
PLoS One; 2017; 12(9):e0184094. PubMed ID: 28910345
[TBL] [Abstract][Full Text] [Related]
11. [Sub-threshold prostate-specific antigen levels after resection of metachronous pulmonary metastases].
Spek A; Faber C; Stief C
Urologe A; 2015 Oct; 54(10):1425-8. PubMed ID: 26223954
[TBL] [Abstract][Full Text] [Related]
12. [Circulating miR-152 helps early prediction of postoperative biochemical recurrence of prostate cancer].
Chen JF; Liao YF; Ma JB; Mao QF; Jia GC; Dong XJ
Zhonghua Nan Ke Xue; 2017 Jul; 23(7):603-608. PubMed ID: 29723452
[TBL] [Abstract][Full Text] [Related]
13. Early prediction of prostate cancer biochemical recurrence and identification of disease persistence using PSA isoforms and human kallikrein-2.
Do Carmo Silva J; Vesely S; Luksanova H; Prusa R; Babjuk M
Tumour Biol; 2021; 43(1):197-207. PubMed ID: 34486998
[TBL] [Abstract][Full Text] [Related]
14. Circulating miRNAs as non-invasive biomarkers to predict aggressive prostate cancer after radical prostatectomy.
Hoey C; Ahmed M; Fotouhi Ghiam A; Vesprini D; Huang X; Commisso K; Commisso A; Ray J; Fokas E; Loblaw DA; He HH; Liu SK
J Transl Med; 2019 May; 17(1):173. PubMed ID: 31122242
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy.
Wenske S; Korets R; Cronin AM; Vickers AJ; Fleisher M; Scher HI; Pettersson K; Guillonneau B; Scardino PT; Eastham JA; Lilja H
Int J Cancer; 2009 Feb; 124(3):659-63. PubMed ID: 19003994
[TBL] [Abstract][Full Text] [Related]
16. [Human kallikreins as tumor markers. Validation of potential marker of prostate cancer in serum and tissue].
Rabien A; Kristiansen G; Diamandis EP; Jung K; Stephan C
Urologe A; 2007 Sep; 46(9):1070-1. PubMed ID: 17605120
[No Abstract] [Full Text] [Related]
17. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
[TBL] [Abstract][Full Text] [Related]
18. Preoperative and postoperative evaluation of prostate-specific antigen in localized prostatic cancer treated by radical prostatectomy.
Zattoni F; Piazza R; Vianello R; Garbeglio A; Pagano F
Eur Urol; 1992; 21 Suppl 1():99-101. PubMed ID: 1385140
[TBL] [Abstract][Full Text] [Related]
19. Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition.
Porzycki P; Ciszkowicz E; Semik M; Tyrka M
Int Urol Nephrol; 2018 Sep; 50(9):1619-1626. PubMed ID: 30014459
[TBL] [Abstract][Full Text] [Related]
20. Combining PHI and miRNAs as Biomarkers in Prostate Cancer Diagnosis and Prognosis.
Ibrahim NH; Abdellateif MS; Thabet G; Kassem SH; El-Salam MA; El-Leithy AA; Selim MM
Clin Lab; 2019 Jul; 65(7):. PubMed ID: 31307177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
